Evidence map›Paper›PMID 33208912›Full record

ArticleOncogene2021

BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.

Anna Han, Timothy J Purwin, Nelisa Bechtel, Connie Liao, Vivian Chua, Erin Seifert, Takami Sato, Zachary T Schug, David W Speicher, J William Harbour and 1 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
  9. Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma.Molecular cancer research : MCR · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Anna HanDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Timothy J PurwinDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.ORCID http://orcid.org/0000-0002-7053-8039
Nelisa BechtelDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Connie LiaoDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Vivian ChuaDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Erin SeifertDepartment of Pathology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Takami SatoDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Zachary T SchugMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0003-4197-8227
David W SpeicherMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, 19104, USA.
J William HarbourBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 33101, USA.
Andrew E AplinDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA. Andrew.Aplin@Jefferson.edu.ORCID http://orcid.org/0000-0002-2734-3244
Thomas Jefferson University · USThe Wistar Institute · USUniversity of Miami · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI AMARAVADI, RAVI K · 2008 to 2023
$37.1M
Targeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1M
The multifaceted role of acetate in cancerDP2CA249950 · NCI · WISTAR INSTITUTE · PI SCHUG, ZACHARY T · 2019 to 2019
$2.7M
Mechanisms of uveal melanoma dormancy and targeted therapy toleranceR01CA253977 · NCI · THOMAS JEFFERSON UNIVERSITY · PI AGUIRRE-GHISO, JULIO A., APLIN, ANDREW ERIC · 2020 to 2024
$2.4M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Mutant BRAF-regulated transcription factors in melanoma progressionR01CA196278 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2015 to 2019
$1.8M
Purchase of a Q Exactive HF mass spectrometer system for metabolomicsS10OD023586 · OD · WISTAR INSTITUTE · PI SPEICHER, DAVID W. · 2017 to 2017
$600k
Purchase of a Seahorse Bioscience XF AnalyzerS10OD023658 · OD · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2017 to 2017
$188k
NCI NIH HHS DP2 CA249950NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA196278NCI NIH HHS R01 CA253977NCI NIH HHS R50 CA221838NIH HHS S10 OD023586
6 · The paper itself

Abstract

Cancer cell metabolism is a targetable vulnerability; however, a precise understanding of metabolic heterogeneity is required. Inactivating mutations in BRCA1-associated protein 1 (BAP1) are associated with metastasis in uveal melanoma (UM), the deadliest adult eye cancer. BAP1 functions in UM remain unclear. UM patient sample analysis divided BAP1 mutant UM tumors into two subgroups based on oxidative phosphorylation (OXPHOS) gene expression suggesting metabolic heterogeneity. Consistent with patient data, transcriptomic analysis of BAP1 mutant UM cell lines also showed OXPHOS

Indexed as

MutationOxidative PhosphorylationCell Line, TumorHumansMelanomaTumor Suppressor ProteinsUbiquitin ThiolesteraseUveal MelanomaUveal NeoplasmsBAP1 protein, humanTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID33208912
PMCPMC7856044
OpenAlexW3098604035

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.